EP1833511A4 - Method of treating brain cancer - Google Patents
Method of treating brain cancerInfo
- Publication number
- EP1833511A4 EP1833511A4 EP06717342A EP06717342A EP1833511A4 EP 1833511 A4 EP1833511 A4 EP 1833511A4 EP 06717342 A EP06717342 A EP 06717342A EP 06717342 A EP06717342 A EP 06717342A EP 1833511 A4 EP1833511 A4 EP 1833511A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- brain cancer
- treating brain
- treating
- cancer
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64126305P | 2005-01-03 | 2005-01-03 | |
| PCT/US2006/000122 WO2006074187A2 (en) | 2005-01-03 | 2006-01-03 | Method of treating brain cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1833511A2 EP1833511A2 (en) | 2007-09-19 |
| EP1833511A4 true EP1833511A4 (en) | 2011-01-19 |
Family
ID=36648123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06717342A Withdrawn EP1833511A4 (en) | 2005-01-03 | 2006-01-03 | Method of treating brain cancer |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1833511A4 (en) |
| JP (1) | JP2008526776A (en) |
| KR (1) | KR20070117547A (en) |
| CN (1) | CN101287369A (en) |
| AU (1) | AU2006204052A1 (en) |
| CA (1) | CA2592971A1 (en) |
| WO (1) | WO2006074187A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750160B2 (en) | 2003-11-13 | 2010-07-06 | Ambit Biosciences Corporation | Isoxazolyl urea derivatives as kinase modulators |
| CN101742910A (en) * | 2007-04-10 | 2010-06-16 | 美瑞德制药公司 | Method of treating brain cancer |
| CA2720987A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Dosages and methods for the treatment of cancer |
| FR2932180B1 (en) * | 2008-06-04 | 2012-08-10 | Centre Nat Rech Scient | DIHYDRO ISO CA-4 AND THE LIKE: CYTOTOXICALLY POWERFUL, INHIBITORS OF TUBULIN POLYMERIZATION |
| MX345400B (en) | 2011-03-15 | 2017-01-30 | Chiesi Farm Spa | Isoxazolidine derivatives. |
| RU2013141933A (en) | 2011-03-15 | 2015-03-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | ISOXAZOLIDINE DERIVATIVES |
| FR3019819B1 (en) * | 2014-04-09 | 2018-03-23 | Centre National De La Recherche Scientifique (Cnrs) | CYTOTOXIC COMPOUNDS INHIBITING TUBULIN POLYMERIZATION |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| FR3080620B1 (en) | 2018-04-27 | 2021-11-12 | Univ Paris Sud | COMPOUNDS WITH TUBULIN POLYMERIZATION INHIBITOR ACTIVITY AND IMMUNOMODULATORY PROPERTIES |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014716A1 (en) * | 1991-02-20 | 1992-09-03 | Pfizer Inc. | 2,4-diaminoquinazolines derivatives for enhancing antitumor activity |
| WO2005003100A2 (en) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| WO2006014420A1 (en) * | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| WO2006074147A2 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL88507A (en) * | 1987-12-03 | 1993-02-21 | Smithkline Beckman Intercredit | 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them |
| CA2265630A1 (en) * | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| AU4317399A (en) * | 1998-05-28 | 1999-12-13 | Parker Hughes Institute | Quinazolines for treating brain tumor |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
-
2006
- 2006-01-03 EP EP06717342A patent/EP1833511A4/en not_active Withdrawn
- 2006-01-03 KR KR1020077017960A patent/KR20070117547A/en not_active Application Discontinuation
- 2006-01-03 CA CA002592971A patent/CA2592971A1/en not_active Abandoned
- 2006-01-03 AU AU2006204052A patent/AU2006204052A1/en not_active Abandoned
- 2006-01-03 JP JP2007549710A patent/JP2008526776A/en active Pending
- 2006-01-03 WO PCT/US2006/000122 patent/WO2006074187A2/en active Application Filing
- 2006-01-03 CN CNA2006800025252A patent/CN101287369A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014716A1 (en) * | 1991-02-20 | 1992-09-03 | Pfizer Inc. | 2,4-diaminoquinazolines derivatives for enhancing antitumor activity |
| WO2005003100A2 (en) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| WO2006014420A1 (en) * | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| WO2006074147A2 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
Non-Patent Citations (2)
| Title |
|---|
| ASSEFA, HAREGEWEIN ET AL: "3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN , 17(8), 475-493 CODEN: JCADEQ; ISSN: 0920-654X, 2003, XP002613543 * |
| RACHID, ZAKARIA ET AL: "The Combi-Targeting Concept: Chemical Dissection of the Dual Targeting Properties of a Series of "Combi-Triazenes"", JOURNAL OF MEDICINAL CHEMISTRY , 46(20), 4313-4321 CODEN: JMCMAR; ISSN: 0022-2623, 2003, XP002613544 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2592971A1 (en) | 2006-07-13 |
| EP1833511A2 (en) | 2007-09-19 |
| WO2006074187A2 (en) | 2006-07-13 |
| KR20070117547A (en) | 2007-12-12 |
| JP2008526776A (en) | 2008-07-24 |
| WO2006074187A3 (en) | 2008-01-10 |
| AU2006204052A1 (en) | 2006-07-13 |
| CN101287369A (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL188746A0 (en) | Treatment of cancer | |
| EP2044026A4 (en) | Method of treatment of glioma brain tumour | |
| EP2144504A4 (en) | Method of treating brain cancer | |
| EP1991230A4 (en) | Methods of treating cancer | |
| EP1885400A4 (en) | Methods of treating brain tumors with antibodies | |
| ZA200802064B (en) | Method for the treatment of acne | |
| EP1833511A4 (en) | Method of treating brain cancer | |
| EP1909854A4 (en) | Method for treating cancer | |
| IL188430A0 (en) | Treatment of tumors | |
| EP1755394A4 (en) | Cancer treatment method | |
| EP1906963A4 (en) | Method of treating ischemia-reperfusion injury | |
| IL183059A0 (en) | Cancer treatment method | |
| IL179323A0 (en) | Cancer treatment method | |
| IL199689A0 (en) | Compounds and method for treatment of cancer | |
| HK1164767A1 (en) | Compounds and methods for the treatment of cancer | |
| IL188728A0 (en) | Methods of treating epileptogenesis | |
| IL238394A0 (en) | Cancer treatment method | |
| EP2225226A4 (en) | Compounds and method for treatment of cancer | |
| IL179359A0 (en) | Cancer treatment method | |
| EP2088862A4 (en) | Cancer treatment method | |
| EP2068911A4 (en) | Methods for treating cancer | |
| EP1802617A4 (en) | Cancer treatment method | |
| GB0520067D0 (en) | Treatment of cancer | |
| IL226363A0 (en) | Compounds and methods for the treatment of cancer | |
| GB2424579B (en) | Method of treating hair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20070629 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1102261 Country of ref document: HK |
|
| R17D | Deferred search report published (corrected) |
Effective date: 20080110 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/517 20060101ALI20080124BHEP Ipc: A01N 43/54 20060101AFI20080124BHEP |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20101222 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20101213BHEP Ipc: A61K 31/4706 20060101ALI20101213BHEP Ipc: A61K 31/5377 20060101ALI20101213BHEP Ipc: A61K 31/517 20060101ALI20101213BHEP Ipc: A01N 43/54 20060101AFI20080124BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20101230 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1102261 Country of ref document: HK |